[eng] The general goal of this thesis has been to progress oncolytic adenovirus therapy for
PDAC, by the incorporation of novel preclinical models to test for patient-specific responses …

Background Pancreatic patient–derived organoids (PDOs) are a well-established model for
studying pancreatic ductal adenocarcinoma (PDAC) carcinogenesis and are potential …

Oncolytic virotherapy shows promise for pancreatic ductal adenocarcinoma (PDAC)
treatment, but there is the need to minimize associated-toxicities. In the current work, we …

Standard‐of‐care regimens for pancreatic ductal adenocarcinoma (PDAC) include a
combination of chemotherapies, which are associated with toxicity and eventually tumor …

Simple Summary If harnessed appropriately, oncolytic viruses offer significant potential as
anti-cancer agents. Such virotherapies can be engineered to replicate inside cancerous …

Purpose: Since drug responses vary between patients, it is crucial to develop pre-clinical or
co-clinical strategies that forecast patient response. In this study, we tested whether RNA …

Recent preclinical and clinical studies have used viral vectors in gene therapy research,
especially nonreplicating adenovirus encoding strategic therapeutic genes for cancer …

HUB's patient-derived organoids (PDOs) are in vitro models that preserve tissue morphology
and original cellular complexity. Additionally, PDOs are compatible with (high) throughput …

Oncolytic adenoviruses (OAd) selectively target and lyse tumor cells and enhance anti-tumor
immune responses. OAds have been used as promising cancer gene therapies for many …

Recombinant adenovirus (rAd) regimens, including replication-competent oncolytic
adenovirus (OAV) and replication-deficient adenovirus, have been identified as potential …